Clinical Trial

High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)

Study acronym: HR-NBL2
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is an international multicenter, open-label, randomized phase III trial including three sequential randomizations to assess efficacy of induction and consolidation chemotherapies and radiotherapy for patients with high-risk neuroblastoma.
Protocol Amendment History 12 amendments
This ClinicalTrials.gov record has been amended 12 times since 2020-01-06; most recent amendment 2025-06-25.
Trial Details
NCT Number NCT04221035
Lead Sponsor Gustave Roussy, Cancer Campus, Grand Paris
Conditions High-Risk Neuroblastoma, Patient With Insufficient Response Chemoimmunotherapy
Enrollment 800 participants
Start Date 2019-11-05
Primary Completion 2026-11 (estimated)
Study Completion 2032-11 (estimated)
Updated on ClinicalTrials.gov 2025-06-26